Envestnet Portfolio Solutions Inc. Buys Shares of 10,269 Dynavax Technologies Co. (NASDAQ:DVAX)

Envestnet Portfolio Solutions Inc. purchased a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,269 shares of the biopharmaceutical company’s stock, valued at approximately $131,000.

A number of other institutional investors also recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in shares of Dynavax Technologies during the fourth quarter valued at approximately $990,000. Nordea Investment Management AB raised its holdings in Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after acquiring an additional 232,690 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Dynavax Technologies by 8.3% during the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after purchasing an additional 82,449 shares during the last quarter. Palumbo Wealth Management LLC purchased a new stake in shares of Dynavax Technologies in the fourth quarter valued at $275,000. Finally, Barclays PLC increased its stake in Dynavax Technologies by 137.4% in the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after purchasing an additional 175,118 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Stock Down 0.3 %

DVAX opened at $13.68 on Friday. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $14.63. The firm has a 50 day moving average price of $13.35 and a 200 day moving average price of $12.49. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market cap of $1.70 billion, a PE ratio of 76.00 and a beta of 1.23.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. The company had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Sell-side analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DVAX. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.